Novo Nordisk's Wegovy wins FDA approval for cutting heart disease risks, in move that could expand insurance coverage
Publishing timestamp: 2024-03-08 15:51:18
Summary
The FDA approved Novo Nordisk's weight loss drug Wegovy for use in reducing the risk of serious cardiovascular complications in adults with obesity and heart disease. This could lead to wider insurance coverage for the drug and similar treatments for obesity. Wegovy has shown significant health benefits beyond weight loss and regulating blood sugar, with a 20% reduction in the risk of heart attack, stroke, and death from cardiovascular causes. The drug is part of a class that suppresses appetite by mimicking a gut hormone. Novo Nordisk is working to increase manufacturing capacity to meet demand.
Sentiment: POSITIVE
Keywords: social issues, united states, breaking news: business, novo nordisk a/s, eli lilly and co, science, business news,